Phase
Condition
Leukemia (Pediatric)
Bone Marrow Disorder
Red Blood Cell Disorders
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥18 years
Confirmed diagnosis of PV without symptomatic splenomegaly
Indication and decision for treatment with ropeginterferon alfa-2b in accordancewith current SmPC
No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolledup to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be ontreatment at the time of enrollment.)
Dated signature of informed consent form
Participation in Patient-Reported Outcome (PRO) assessment in German language andcompletion of questionnaire at time of study enrollment
Other criteria according to current Summary of Product Characteristics
Exclusion
Exclusion Criteria:
Participation in an interventional clinical trial (except follow-up)
Other contraindications according to current Summary of Product Characteristics
Study Design
Connect with a study center
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde
Hannover, Niedersachsen 30161
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.